Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/6/2026

1. HUBS
2. WDC
3. SNDK
4. KVYO
5. APP
6. ZG
7. DASH
8. XYZ
9. DOX
10. PAYC

Go back to Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
Merck & Co. (NYSE: MRK) Delayed: 128.39 +0.06 (0.05%)
Previous Close $128.33    52 Week High $65.46 
Open $130.96    52 Week Low $47.97 
Day High $131.08    P/E 87.34 
Day Low $127.80    EPS $1.47 
Volume 3,852,350